Secukinumab after anti-tumour necrosis factor-α therapy: a phase III study in active rheumatoid arthritis

Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double-Blind, Active Comparator- and Placebo-Controlled Study

(2017) Francisco J. Blanco et al.   Arthritis & Rheumatology

Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)

(2016) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Rheumatoid arthritis

(2016) Josef S Smolen et al.   LANCET

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2015) Iain B McInnes et al.   LANCET

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis

(2015) Dominique Baeten et al.   NEW ENGLAND JOURNAL OF MEDICINE

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis

(2015) Philip J. Mease et al.   NEW ENGLAND JOURNAL OF MEDICINE

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

(2014) Richard G. Langley et al.   NEW ENGLAND JOURNAL OF MEDICINE

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

(2013) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

(2009) G. Jones et al.   ANNALS OF THE RHEUMATIC DISEASES